Evolocumab

Category: biologic

Aliases: Repatha

Pharmacological Mechanism

Fully human IgG2 mAb binding PCSK9. Same mechanism as alirocumab. FOURIER trial 2017 established CV event reduction. Glagov trial showed atherosclerosis regression on IVUS.

Half-Life (t½)

SC: 336h

Dosing Guidelines

• SC: Typical 140mg (Range: 140 - 140 mg)

Target Organ Systems

• cardiovascular

Interactions

• Alirocumab